MEDIVIR AB NPVMEDIVIR AB NPVMEDIVIR AB NPV

MEDIVIR AB NPV

No trades
See on Supercharts

0GP7 fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Medivir AB engages in the development of pharmaceuticals products. The firm focuses on the discovery and development of transformative active cancer drugs. Its portfolio includes proprietary pipelines such as remetinostat, birinapant, MV-818, MV-828, and MIV-711 projects, and partnership pipeline which covers xerclear and MIV-802 project. The company was founded in 1988 and is headquartered in Huddinge, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
0GP7 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company